Shearman & Sterling advised the underwriters in the global offering of Orphazyme A/S consisting of 3,966,146 American depositary shares (each representing one ordinary share) in its initial public offering in the U.S. and 3,650,000 ordinary shares in a European private placement, resulting in gross proceeds to Orphazyme of approximately $83.8 million. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “ORPH” on September 29, 2020. Orphazyme’s ordinary shares are listed on Nasdaq Copenhagen A/S under the ticker symbol “ORPHA.”
BofA Securities, Cowen and Guggenheim Securities acted as the global coordinators and joint book-running managers and Danske Markets acted as the lead manager of the global offering. In addition, BofA Securities, Cowen and Guggenheim Securities (in each case, or their affiliates) and Danske Bank acted as joint book-running managers in the European private placement.
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. Orphazyme is harnessing amplification of Heat-Shock Proteins in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, Orphazyme’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Amyotrophic Lateral Sclerosis, sporadic Inclusion Body Myositis and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland.
The Shearman & Sterling team below also included associates Jessica Riley and Alex Liebmann.